Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.55 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.55 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.55 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.55 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.55 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.54 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.54 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.54 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.54 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 2/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | MAOB | P27338 | 4/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL683157 | 0.85 | RAB9A (0.50) | LMNACYP1A2PTGS1SLC6A2CYP2C19 | |
| SCHEMBL6564405 | 0.85 | KCNA3 (0.56) | LMNAPTGS1CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL9808056 | 0.85 | LMNA (0.72) | LMNACYP1A2PTGS1SLC6A2CYP2C19 | |
| SCHEMBL14443375 | 0.83 | HTR1A (0.54) | L3MBTL1MAPT | |
| SCHEMBL11692748 | 0.82 | LTA4H (0.61) | LTA4H | |
| SCHEMBL14118641 | 0.82 | LSS (0.54) | HDAC6CHRNB2CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL10770569 | 0.81 | RAB9A (0.49) | LMNACYP1A2PTGS1SLC6A2CYP2C19 | |
| SCHEMBL8634028 | 0.80 | LMNA (0.60) | LMNACYP1A2PTGS1SLC6A2CYP2C19 | |
| SCHEMBL7595917 | 0.80 | LMNA (0.60) | LMNACYP1A2PTGS1SLC6A2CYP2C19 | |
| SCHEMBL6560429 | 0.80 | KCNA3 (0.50) | LMNACHRNB2CHRNB4CHRNA3CHRNA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130261178-A1 | PHENOXYPROPANOL DERIVATIVES AND THEIR USE IN TREATING CARDIAC AND CARDIOVASCULAR DISEASES | MISTRY SHAILESH (GB) | 2013-10-03 | — | — | US | disclosed |
| EP-2590937-A1 | PHENOXYPROPANOL DERIVATIVES AND THEIR USE IN TREATING CARDIAC AND CARDIOVASCULAR DISEASES | The University Of Nottingham (GB) | 2013-05-15 | — | — | EP | disclosed |
| WO-2012004549-A1 | PHENOXYPROPANOL DERIVATIVES AND THEIR USE IN TREATING CARDIAC AND CARDIOVASCULAR DISEASES | THE UNIVERSITY OF NOTTINGHAM (GB) | 2012-01-12 | — | — | WO | disclosed |
| US-7250246-B2 | Positive resist composition and pattern formation method using the same | FUJIFILM CORPORATION (JP) | 2007-07-31 | — | — | US | disclosed |
| US-7250246-B2 | Positive resist composition and pattern formation method using the same | FUJIFILM CORPORATION (JP) | 2007-07-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130261178-A1 | PHENOXYPROPANOL DERIVATIVES AND THEIR USE IN TREATING CARDIAC AND CARDIOVASCULAR DISEASES | NR3C2, NPR3, ADRB3 | LMNA 615/4885CYP1A2 371/4885PTGS1 1408/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.